IMRN News and Press, Immuron Limited

MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on...

2026-02-25 06:14:24 ET More on Immuron Immuron Limited (IMRN) Presents at Emerging Growth Conference 89 - Slideshow Seeking Alpha’s Quant Rating on Immuron Historical earnings data for Immuron Financial information for Immuron Read the full a...

Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY). Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) rai...

Sales Highlights (unaudited): MELBOURNE, Australia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan ® , an over-the-coun...

Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella Uniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: ...

Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND number (032095) for the IMM-529 application IND 32095 is Immuron’s Investigat...

2025-10-31 09:36:53 ET More on Immuron Seeking Alpha’s Quant Rating on Immuron Financial information for Immuron Read the full article on Seeking Alpha For further details see: Immuron reports delay in Travelan study data

IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan ® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown MELB...

Sales Highlights (unaudited): MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan ® , an ove...

Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continue...